Unknown

Dataset Information

0

Intra-Anal Imiquimod Cream against Human Papillomavirus Infection in Men Who Have Sex with Men Living with HIV: A Single-Arm, Open-Label Pilot Study.


ABSTRACT: Men who have sex with men (MSM) living with HIV have a high prevalence and incidence of anal high-risk human papillomavirus (hrHPV) and anal cancer. We conducted an open-label, single-arm pilot study to examine the tolerability of imiquimod cream among MSM aged ≥18 years, living with HIV, who tested positive for anal hrHPV at Melbourne Sexual Health Centre between April 2018 and June 2020. We instructed men to apply 6.25 mg imiquimod intra-anally and peri-anally 3 doses per week for 16 weeks (period 1) and then one dose per week for a further 48 weeks (period 2). Twenty-seven MSM enrolled in period 1 and 24 (86%) applied at least 50% of doses. All men reported adverse events (AEs), including 39.5% grade 1, 39.5% grade 2, and 21% grade 3 AEs on at least one occasion. Eighteen MSM (67%) temporarily stopped using imiquimod during period 1, most commonly due to local AEs (n = 11) such as irritation and itching. Eighteen MSM continued in period 2 and all applied at least 50% of doses with no treatment-limiting AEs reported. Imiquimod 3 doses per week caused local AEs in most men and was not well tolerated. In contrast, once-a-week application was well tolerated over 48-weeks with no treatment-limiting AEs.

SUBMITTER: Durukan D 

PROVIDER: S-EPMC8509144 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2022-01-13 | GSE193351 | GEO
| S-EPMC7035349 | biostudies-literature
| S-EPMC4993367 | biostudies-literature
| S-EPMC5967740 | biostudies-literature
| S-EPMC6434585 | biostudies-literature
| S-EPMC8627386 | biostudies-literature
| S-EPMC8562516 | biostudies-literature
| S-EPMC8528397 | biostudies-literature
| S-EPMC3883166 | biostudies-literature
| S-EPMC6552657 | biostudies-literature